Answers are grounded in this paper and cite their sources.
(1993). Treatment of Relapsed or Refractory AML with Intermediate-dose Arabinosylcytosine (Ara-C): Confirmation of the Importance of Ara-C Triphosphate Formation in Mediating Response to Ara-C. Leukemia & Lymphoma: Vol. 10, No. sup1, pp. 115-121.
No takes yet. Share an insight, caveat, or question.
Estey et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: